Search

everythinglearnresearchcommunity

for

Search:↓

Hair regrowth and gender transition using finasteride, estrogen, and spironolactone. Significant hair regrowth and personal transformation were achieved through hormone replacement therapy.

A user shared their positive experience with a hair transplant performed by Dr. Timothy Carman, using 1100 grafts via FUT surgery, and reported satisfaction with the results and minimal scarring. The user continues to use minoxidil and finasteride for hair maintenance.

Concerns about the potential high cost of new hair loss treatments, pp405 and gt20029, were discussed, with some users willing to pay a premium if they are effective. Alternatives like finasteride and minoxidil are mentioned as current, more affordable options, and there is speculation about future generic versions and black market availability.

The user experienced significant hair regrowth after 2.5 years of using Minoxidil 5% and hormone replacement therapy (HRT) with Lupron, despite initial scalp irritation. Finasteride was ineffective for them.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

OP developed hives after using Kx 826 (Pyrilutamide) 1% twice daily for 3 weeks. The hives appeared on the arms, chest, and groin area.

The user has been on a comprehensive hair loss treatment regimen for four years, including Dutasteride, topical and oral Minoxidil, and various other treatments, but has seen little progress and is considering a hair transplant. Despite trying multiple therapies, including PRP and exosome injections, the user is still experiencing hair thinning and is hesitant about trying peptides due to potential cancer risks.

A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.

The user shared progress 128 days after a DHI hair transplant with 4261 grafts, using Finasteride, Minoxidil, Cutihance Men tablets, Omega-3, Vitamin D3 with K2, and one session of GFC PRP. They seek feedback on their progress compared to others' experiences.

The conversation is about a user obtaining a compounded treatment for hair loss, including 0.1% latanoprost, 0.2% melatonin, and 1% cetirizine. The user also uses 2.5 mg dutasteride, 5 mg minoxidil, and RU58841 daily, and is at Norwood 2.

N-Acetyl-Cysteine (NAC) was found to improve hair parameters in men with early-onset androgenetic alopecia, showing increased terminal hair count and decreased vellus hair count, with good tolerability. NAC, used alone or with minoxidil, may help due to its antioxidant properties, though its effectiveness can vary among individuals.

The conclusion of the conversation is that some users have seen positive results with the use of finasteride and minoxidil for hair loss, while others have not. It is mentioned that consistent use of these treatments is necessary to maintain results.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

The user is using minoxidil, finasteride, dutasteride, and clobetasol, along with needling, to combat hair loss. They are considering stopping treatment if no improvement is seen.

The user experienced significant hair regrowth using finasteride, minoxidil, and microneedling, but saw a decline after reducing treatments and stopping gym workouts. They plan to restart microneedling and consider a hair transplant in the future.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

An 18-year-old male has been taking oral finasteride 0.25 mg daily for almost four months to address hairline recession, experiencing mild sexual side effects like softer erections and lower libido. He also uses Tugain 5%, ketoconazole, and vitamins, noticing slowed shedding but no major regrowth, and seeks advice on managing side effects and hair loss.

A 20-year-old user experienced worsening hair loss despite using various treatments including topical and oral minoxidil, finasteride, and dutasteride. Other users suggested additional treatments like JAK inhibitors, RU58841, and lifestyle changes, but the user remains skeptical and frustrated.

User considers trying AAPE for hair restoration, costing $700 for 6 months. Others discuss its potential effectiveness and mention a study with promising results.

The conversation discusses the use of dutasteride and finasteride for hair loss, including switching between them, optimal dosing, and managing side effects. The user has transcriptions of videos on these topics and offers them to others interested.

The conversation is about the anticipation and uncertainty regarding the release of GT20029 Phase 2 results for hair loss treatment. Users express hope for its effectiveness and minimal side effects compared to other treatments like Pyri and HMI115.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

The conversation discusses hair loss treatments, including minoxidil, finasteride, biotin, folic acid, zinc, micro-needling, niacin, and cipaxil, with the user preparing for a hair transplant. The user experiences side effects with topical finasteride and is hesitant to try oral dutasteride.

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.

The user has tried various treatments for hair loss, including finasteride, dutasteride, and oral minoxidil, but is considering a hair transplant due to insufficient progress. Some users suggest that the treatments have at least stabilized hair loss, and recommend consulting clinics for a potential hair transplant while continuing medication.

The conversation discusses verteporfin as a potential treatment for hair regeneration, which could lead to unlimited hair transplants by healing the donor area. Some users are considering using verteporfin now, while others are hopeful it will be available for future hair transplants.

PP405 is being discussed as a potential treatment for hair loss, with uncertainty about its effectiveness compared to existing treatments like finasteride, dutasteride, and minoxidil. There is cautious optimism, but its impact on hair transplants remains unclear.

The conversation discusses a hair loss treatment involving a hair transplant of approximately 2500 grafts to the frontal area, daily use of finasteride, twice-daily topical minoxidil, and daily caffeine shampoo since the hair transplant procedure. One person is skeptical about the improvement in the crown area with just finasteride and minoxidil.

The conversation is about a user seeking advice on adding GHK-Cu to RU58841 for hair loss treatment, while already using oral minoxidil, dutasteride, ketoconazole shampoo, and considering LLLT. They are unsure about the concentration and carrier solution for GHK-Cu.